Copyright
©The Author(s) 2022.
World J Diabetes. Dec 15, 2022; 13(12): 1066-1095
Published online Dec 15, 2022. doi: 10.4239/wjd.v13.i12.1066
Published online Dec 15, 2022. doi: 10.4239/wjd.v13.i12.1066
Start year | Institution (Nation) | Type of wounds | Intervention | Autologous/Allogeneic | Administration, frequency | Patients number | Follow-up period | Outcome measures | Phase | Study design | ClinicalTrials.gov identifier | Status |
2022 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (China) | Full-layer skin wounds | Adipose tissue derived exosomes(200-300 mL of the subject adipose tissue) | Autologous | Applied directly to the wound (mixed with sterile hydrogel), twice a week | 5 | 4 wk | Primary: Percentage of wound healing | Not Applicable | Non-randomized, single group assignment, open label | NCT05475418 | Not yet recruiting |
2015 | Kumamoto University (Japan) | Intractable cutaneous ulcers (e.g., rheumatic disease, peripheral arterial disease, chronic venous insufficiency, decubitus or burns) | Plasma-derived exosomes (Plasma samples will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer.) | Autologous | Applied to the ulcer, daily | 5 | 28 d | Primary: Ulcer size (length, width, depth) | Early Phase 1 | Non-randomized, single group assignment, open label | NCT02565264 | Unknown |
Secondary: Pain of cutaneous wounds (VAS) | ||||||||||||
2023 | Aegle Therapeutics (USA) | Dystrophic Epidermolysis Bullosa (DEB); chronic wounds (< 20% closure of wound during observation period); 10-50 cm2 | Bone marrow mesenchymal stem cells derived extracellular vesicle (AGLE-102) | Allogeneic | Multiple administrations of 2 ascending dose levels of AGLE-102; (up to 6 administrations); (each administration will occur 14 ± 7 d but no less than 7 d apart); (each administration no more than 3 mo); (wound closes prior to 6 administrations, no additional doses will be given) | 10 | 8 mo; if the wound closes before receiving all 6 doses, for 4 mo after the wound closes | Primary: Dose limiting toxicity | Phase 1/2 | Non-randomized, multicenter, ascending dose, single group assignment, open label | NCT04173650 | Not yet recruiting |
Secondary: Wound size | ||||||||||||
2019 | Mayapada Hospital (Indonesia) | Chronic wounds | Human Wharton's Jelly mesenchymal stem cells conditioned medium (WJ-MSC-CM) | Allogeneic | Applied to the wound (the conditioned medium gel), every week | 38 | 2 wk | Primary: Success rate of chronic ulcer healing | Phase 1 | Non-randomized, single group assignment, open label | NCT04134676 | Completed |
- Citation: Wu J, Chen LH, Sun SY, Li Y, Ran XW. Mesenchymal stem cell-derived exosomes: The dawn of diabetic wound healing. World J Diabetes 2022; 13(12): 1066-1095
- URL: https://www.wjgnet.com/1948-9358/full/v13/i12/1066.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i12.1066